SHR-A1811 for HER2-positive recurrent or metastatic cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug, SHR-A1811, that targets a protein called HER2 found on some cervical cancer cells. It's for women whose cervical cancer has returned or spread and is not responding to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 75 years old.
- You have cervical cancer that has come back or spread, and your tumor has the HER2 protein.
- You are willing to sign a consent form and follow the study schedule.
- You have not had untreated or active brain metastases.
- You do not have other active cancers, serious heart or lung problems, or a history of certain lung conditions.
- You agree to use birth control if you could become pregnant, and you are not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug combination called SHR-A1811 can help people with cervical cancer that has come back or spread. It aims to find a better treatment option for those who have limited choices.
This trial tests a new drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after the first four rounds of chemotherapy before surgery. The goal is to see if this drug can improve outcomes for patients who need a different treatment approach.
This study tests a new drug called SHR-A1811, given by different methods, to find the best way to treat advanced HER2-positive breast cancer. It may help if you have had few treatments so far and have not had this type of drug before.
This trial tests a new targeted drug, SHR-A2102, for people with advanced gynecological cancers (like ovarian, uterine, or cervical) that have not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells, which may help control the cancer.
This trial tests a new drug, SHR-A1811, for people with HER2-positive stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this drug can help when standard anti-HER2 therapy stops working.
This trial tests an investigational drug called SHR-A1811 in people with non-small cell lung cancer that has spread or cannot be removed by surgery and has a HER2 alteration. The goal is to see if the drug is effective and safe for this type of cancer.
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.